MINNEAPOLIS, MN--(Marketwire - September 23, 2008) - Virogen, Inc. (PINKSHEETS: VRGI), the developer and patent holder of a revolutionary vaccine to combat Newcastle disease, a deadly disease that kills chickens worldwide, announced that a 15 to 1 forward split of the company’s stock was approved at a Board of Directors Meeting on September 18, 2008. The execution of this stock split will take place on Friday, October 31, 2008 and will be effective for all shareholders of record as of that date. While this measure will not change a shareholder’s equity, it is intended to offer a tremendous increase in shareholder’s leverage and liquidity thus enhancing the value of the stock.
